

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

65-049

Bioequivalence Review(s)

BIOEQUIVALENCY COMMENTS TO BE PROVIDED TO THE APPLICANT.

ANDA: 65-049

APPLICANT: Clay-Park Labs, Inc.

DRUG PRODUCT: Clindamycin Phosphate Pledgets, 1%

The Division of Bioequivalence has completed its review and has no further questions at this time.

Please note that the bioequivalency comments provided in this communication are preliminary. These comments are subject to revision after review of the entire application, upon consideration of the chemistry, manufacturing and controls, microbiology, labeling, or other scientific or regulatory issues. Please be advised that these reviews may result in the need for additional bioequivalency information and/or studies, or may result in a conclusion that the proposed formulation is not approvable.

Sincerely yours,



Dale P. Conner, Pharm. D.

Director

Division of Bioequivalence

Office of Generic Drugs

Center for Drug Evaluation and Research